[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC – Authors' reply

We thank Takashi Kokudo and colleagues for their interest in our article and their positive comments. As these authors point out, the Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy recommends a single treatment for each clinical scenario and is not tailored to individual tumour and patient characteristics. We agree that biomarkers are needed to stratify patients for appropriate treatment.

Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Val érie Vilgrain, Helena Pereira, Aurelia Dinut, Gilles Chatellier Tags: Correspondence Source Type: research